Dietary Intake of n-6 Fatty Acids Modulates Effect of Apolipoprotein A5 Gene on Plasma Fasting Triglycerides, Remnant Lipoprotein Concentrations, and Lipoprotein Particle Size by Lai, Chao-Qiang et al.
ISSN: 1524-4539 
Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online
72514
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
DOI: 10.1161/CIRCULATIONAHA.105.577296 
 2006;113;2062-2070; originally published online Apr 24, 2006; Circulation
Ordovas 
Adiconis, Yueping Zhu, Laurence D. Parnell, Katherine L. Tucker and Jose M. 
Chao-Qiang Lai, Dolores Corella, Serkalem Demissie, L. Adrienne Cupples, Xian
 Lipoprotein Particle Size: The Framingham Heart Study
on Plasma Fasting Triglycerides, Remnant Lipoprotein Concentrations, and 
Dietary Intake of n-6 Fatty Acids Modulates Effect of Apolipoprotein A5 Gene
 http://circ.ahajournals.org/cgi/content/full/113/17/2062
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://circ.ahajournals.org/subscriptions/
Subscriptions: Information about subscribing to Circulation is online at 
 at SWETS SUBS SERV-#54225388 on May 14, 2010 circ.ahajournals.orgDownloaded from 
Dietary Intake of n-6 Fatty Acids Modulates Effect of
Apolipoprotein A5 Gene on Plasma Fasting Triglycerides,
Remnant Lipoprotein Concentrations, and Lipoprotein
Particle Size
The Framingham Heart Study
Chao-Qiang Lai, PhD; Dolores Corella, PhD; Serkalem Demissie, PhD; L. Adrienne Cupples, PhD;
Xian Adiconis, MSc; Yueping Zhu, MSc; Laurence D. Parnell, PhD;
Katherine L. Tucker, PhD; Jose M. Ordovas, PhD
Background—Apolipoprotein A5 gene (APOA5) variation is associated with plasma triglycerides (TGs). However, little
is known about whether dietary fat modulates this association.
Methods and Results—We investigated the interaction between APOA5 gene variation and dietary fat in determining
plasma fasting TGs, remnant-like particle (RLP) concentrations, and lipoprotein particle size in 1001 men and 1147
women who were Framingham Heart Study participants. Polymorphisms 1131TC and 56CG, representing 2
independent haplotypes, were analyzed. Significant gene–diet interactions between the 1131TC polymorphism and
polyunsaturated fatty acid (PUFA) intake were found (P0.001) in determining fasting TGs, RLP concentrations, and
particle size, but these interactions were not found for the 56CG polymorphism. The 1131C allele was associated
with higher fasting TGs and RLP concentrations (P0.01) in only the subjects consuming a high-PUFA diet (6% of
total energy). No heterogeneity by sex was found. These interactions showed a dose-response effect when PUFA intake
was considered as a continuous variable (P0.01). Similar interactions were found for the sizes of VLDL and LDL
particles. Only in carriers of the 1131C allele did the size of these particles increase (VLDL) or decrease (LDL) as
PUFA intake increased (P0.01). We further analyzed the effects of n-6 and n-3 fatty acids and found that the
PUFA–APOA5 interactions were specific for dietary n-6 fatty acids.
Conclusions—Higher n-6 (but not n-3) PUFA intake increased fasting TGs, RLP concentrations, and VLDL size and
decreased LDL size in APOA5 1131C carriers, suggesting that n-6 PUFA–rich diets are related to a more atherogenic
lipid profile in these subjects. (Circulation. 2006;113:2062-2070.)
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The impact of hypertriglyceridemia on coronary heart diseaserisk has long been a matter of debate; however, evidence
supporting the prognostic value of this lipid fraction has been
gained during the past decade.1,2 Triglyceride (TG)–rich lipopro-
teins comprise a great variety of nascent and metabolically
modified lipoprotein particles, and they are especially relevant
during the postprandial state.3 Remnant lipoproteins have also
been shown to promote atherogenesis,4–6 and plasma remnant-
like particles (RLPs) can be measured by an antibody-based
assay.7 In the Framingham Offspring Study,8 RLPs were signif-
icantly increased in women with diabetes and in men compared
with control subjects without diabetes.
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Apolipoprotein A5 (APOA5)9,10 is found preferentially
on HDL but is thought to transfer to VLDL during the
postprandial state.11 Despite its very low levels in plasma,
APOA5 is an important regulator of TG-rich lipoprotein
(TRL) metabolism.12 Two mechanisms have been pro-
posed. The first suggests a role of APOA5 in VLDL
assembly13,14; the second supports the possibility that
APOA5 may be an activator of intravascular TG hydrolysis
by lipoprotein lipase (LPL).15–17 However, both proposals
are not mutually exclusive, and these mechanisms may be
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working simultaneously or alternatively, depending on
specific metabolic situations.
Several common APOA5 single-nucleotide polymorphisms
(SNPs) have been associated with increased plasma total TG,
RLP, and VLDL concentrations.18 –22 Moreover, current
knowledge suggests an association between APOA5 and
postprandial lipemia that could be modulated by the type of
dietary fat.23,24 In this regard, polyunsaturated fatty acids
(PUFAs) are known modulators of gene expression.25 Along
these lines, we have reported that dietary PUFAs interact with
the leucine to valine (L162V) substitution at the peroxisome
proliferator–activated receptor- (PPAR-) gene in deter-
mining plasma TG and apolipoprotein C3 concentrations in
the Framingham Study participants.26 Considering that
PPAR- is a nuclear transcription factor regulating multiple
genes involved in lipid metabolism (including APOA527), our
previous results prompted us to examine the hypothesis that
PUFA intake may modulate the effect of APOA5 variants on
lipid metabolism. Moreover, given the different cardiovascu-
lar protection attributed to n-6 and n-3 PUFAs,28 we exam-
ined their potential interactions with APOA5 variants in a
large population-based study, the Framingham Heart Study.
Methods
Study Design and Subjects
The study sample consisted of 2148 subjects who participated in the
Framingham Offspring Study.29 Lipids, other cardiovascular disease
(CVD) risk factors, and dietary intake were recorded for subjects
who participated in the fifth examination, conducted between 1992
and 1995 (n3515). DNA was obtained from 1987 to 1991. The
Institutional Review Board for Human Research at Boston Univer-
sity and Tufts University/New England Medical Center approved the
protocol of the present study. All participants provided written
informed consent.
The present study included only subjects with phenotypic data and
complete dietary information for whom APOA5 gene variants were
examined. Subjects taking lipid-lowering medications as well as
subjects with any missing data on control variables (age, body mass
index [BMI], smoking, alcohol consumption, diabetes status,
-blocker use, and estrogen use in women) were excluded from our
analyses. Thus, data for 1001 men and 1147 women who met the
above criteria were analyzed. Because nearly all subjects were white,
no control for ethnicity was needed. Although in the Framingham
Study recruitment of families was planned,29 in this specific cycle
most participants were unrelated, and the number of individuals
within each family included in the present study was very low. Thus,
the 1147 women considered in the present study were distributed in
893 pedigrees, and 752 (65%) were singletons. In the nonsingletons,
113 women were unrelated, and the others were mostly siblings and
cousins. The 1001 men in the present study were distributed in 814
pedigrees, and 697 of the 1001 (70%) were singletons. In the
families, 53 men were unrelated, and the others were mostly siblings
and cousins.
Genetic Analysis
Genomic DNA was isolated from peripheral blood leukocytes by
standard methods. APOA5 SNPs 1131TC(rs662799),
3AG(rs651821), IVS3476GA(rs2072560), and
1259TC(rs2266788) and 56CG(rs3135506) were genotyped as
previously described21,22 by use of the ABI Prism SNapShot multi-
plex system (Applied Biosystems, Foster City, Calif).
Measurement of Plasma Lipid, Lipoprotein,
and Apolipoprotein
The standardized procedures for sample collection and biochemical
analysis for TGs, total cholesterol, LDL cholesterol, and HDL
cholesterol have been described previously.30 VLDL and LDL
subclass distributions were determined by proton nuclear magnetic
resonance spectroscopy.31 Measurements of RLP-TG and RLP
cholesterol (RLP-C) concentrations have previously been described.7
Dietary Assessment
Dietary intake was estimated with the semiquantitative Willett
food-frequency questionnaire (Rimm et al32), which specified serv-
ing sizes. This questionnaire has been validated for total PUFA
intake as well as n-3 and n-6 fatty acids (FAs).32,33 Intakes of total
fat, saturated fatty acids (SFAs), monounsaturated fatty acids (MU-
FAs), total PUFAs, and n-3 and n-6 PUFAs were expressed as
percentages of total energy and were included in analyses as both
continuous and categorical variables. To construct categorical vari-
ables, intakes were classified into 2 groups according to the mean
value of the population (ie, groups had intakes below and above the
mean). In addition, we considered together as n-3 PUFA the dietary
intake of -linolenic acid, eicosapentaenoic acid, docosahexaenoic
acid, and docosapentaenoic acid. Linoleic acid and arachidonic acid
were considered together as n-6 PUFA. Tertiles of PUFA intakes
(n-6 and n-3) were also considered.
Statistical Analyses
We examined all continuous variables for normality of distribution.
TG, RLP-TG, and RLP total cholesterol (RLP-C) concentrations
were log-transformed. Results were presented as the antilog of the
estimated log values. The relationship between APOA5 genotypes,
dietary PUFAs, and plasma lipid–related measures was evaluated by
analysis of covariance techniques. Because the present study in-
volved some correlated data that were due to familial relationships
(siblings and cousins), we controlled for familial relationships. We
used 2 approaches to accomplish these analyses. First, a generalized
linear mixed-model approach, which assumed an exchangeable
correlation structure among all members of a family (PROC MIXED
in SAS, Cary, NC), was used. Second, because this approach could
not accurately represent the true correlation structure within these
pedigrees, we used a measured-genotype approach as implemented
in SOLAR, a variance component-analysis computer package for
quantitative traits measured in pedigrees of arbitrary size.34 In these
analyses, we used several different models to adjust for potential
confounders. After having checked that the results obtained using the
generalized mixed model were similar to those of the SOLAR
approach because of the large number of unrelated subjects in this
sample, we decided to use the generalized mixed model for the
adjustment of familial relationships. The interactions between di-
etary PUFAs (as a continuous or as a categorical variable) and the
APOA5 polymorphisms were tested in a hierarchical multivariate-
interaction model after controlling for potential confounders, includ-
ing sex, age, BMI, smoking, alcohol consumption, total energy, fat
and carbohydrate intakes, diabetes status, -blocker use, menopausal
status, and estrogen use (in women). These analyses were performed
for the whole sample and for men and women separately in order to
verify the homogeneity and the magnitude of the effect. Standard
regression diagnostic procedures, including multicollinearity tests,
homogeneity of variance tests, normal plots of the residuals, and
residuals by Student t test, were used to ensure the appropriateness of
these models. The population means for PUFA intake and for other
types of fat were considered the cutoff points to dichotomize these
variables. When PUFA intake was considered as a continuous
variable, its interaction with the APOA5 polymorphism was depicted
by computing the predicted values for each individual from the
adjusted regression model and plotting these values against PUFA
intake depending on the APOA5 genotype. The haplotype analysis
was carried out as previously described.22 The pairwise linkage
disequilibria (LDs) between SNPs at the APOA5 locus were esti-
mated as correlation coefficient R, with the HelixTree program using
unrelated subjects. Inference and possible haplotypes were computed
via an expectation-maximization algorithm.22 All reported statistical
tests were 2 sided. To minimize type I errors, which are increased
because of the high number of comparisons, only values of P0.01
were considered statistically significant.
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The authors had full access to the data and take full responsibility
for its integrity. All authors have read and agreed to the manuscript
as written.
Results
Information about demographic, biochemical, dietary in-
take, and genotypic data are provided in Table 1. Five
APOA5 SNPs (1131TC, 3AG, 56CG,
IVS3476GA, and 1259TC) were analyzed. Genotype
frequencies did not deviate from Hardy-Weinberg equilib-
rium expectations. Allele frequencies for the rare alleles
listed above were 0.069, 0.071, 0.059, 0.064, and 0.072,
respectively. As previously shown,22 4 of the APOA5 SNPs
(1131TC, 3AG, IVS3476GA, and 1259TC)
were in strong LD with each other and shared the same
haplotype. Pairwise LD coefficient R values between the
1131TC SNP and SNPs 3AG, IVS3476GA,
and 1259TC in unrelated subjects were 1, 1, and 1,
respectively (P0.001). The haplotype defined by these
SNPs was named haplotype APOA5*2.18 In contrast, SNP
56CG was independent of the aforementioned SNPs,
representing a different haplotype (ie, APOA5*3).18 Pair-
wise LD coefficient R between the 1131TC SNP and
56CG was 0.063. Furthermore, we investigated gene–
diet interactions determining plasma TGs, TRL concentra-
tions, and lipoprotein particle sizes for each of the 5 SNPs
as well as for the most prevalent haplotypes (11111
[representing 86.3% of all haplotypes] and 22122 and
11211 [accounting for 6.2% and 5.7%, respectively]). As
expected, the analyses of each of the 4 SNPs in strong LD
revealed the same interactions with the dietary PUFA
intake on the variables examined, whereas no significant
interactions with fat intake were observed for SNP 56CG
(data not shown). Accordingly, in the haplotype associa-
tion analysis, we obtained statistically significant interac-
tions (P0.01) between PUFA intake and the 22122
haplotype in determining TRL in men and women. No
significant interactions were obtained when the 11211
haplotype was analyzed. Because the haplotype analysis
did not show better results than did the SNP analysis with
the 1131TC polymorphism, we considered this SNP to
be a tag SNP of the APOA5*2 haplotype.
First, to examine the interaction between 1131TC
SNP and PUFA intake, we dichotomized dietary PUFA
according to the population mean (5.921.7%, 6%).
Homozygotes (CC) and heterozygotes (TC) of the rare
allele were combined to increase statistical power. Sepa-
rate models were fitted for men and women, and although
the magnitude of the effect was slightly greater in men,
similar directions of effects were observed. Moreover, the
homogeneity by sex was also confirmed by examining the
probability value of the corresponding interaction term
with sex (P0.05 for each parameter examined). There-
fore, men and women were analyzed together. After
multivariate control for potential confounders, a statisti-
cally significant interaction (P0.001) between SNP
1131TC and PUFA intake (6% or 6% of energy)
on TG concentration was found (Figure 1A). In the
adjusted model, the 1131C allele was associated with an
increase in fasting TG (21%, P0.002) only in subjects
consuming 6% of energy from PUFA. However, mean
fasting TG concentrations were not statistically higher in
carriers of the 1131C allele compared with the TT
homozygotes when the PUFA consumption was low
(P0.600). We observed similar and significant interac-
tions between PUFA consumption and SNP 1131TC
on RLP-TG (P0.001) and RLP-C (P0.001). As ob-
served for fasting TGs, concentrations of RLP-TG in
TABLE 1. Demographic, Biochemical, Dietary, and
Genotypic Data
Characteristics of Participants
According to Sex
Men
(n1001)
Women
(n1147)
Age, y 50.89.9 50.19.6
BMI, kg/m2 27.63.8 25.95.5
LDL-C, mg/dL 13533 12735
HDL-C, mg/dL 4411 5615*
TG, mg/dL 13597 105101*
RLP-TG,† mg/dL 30.745.0 22.270.2*
RLP-C,† mg/dL 8.546.79 7.136.31*
LDL diameter, nm 20.690.59 21.080.46
VLDL diameter, nm 48.289.24 44.208.58*
Glucose, mg/dL 97.023.0 91.119.3*
Energy intake, kcal/d 2004643 1745576*
Total fat, g/d 67.127.6 56.923.8*
SFA, % of energy 10.62.9 10.32.9*
MUFA, % of energy 11.52.6 11.02.6*
n-6 PUFA, % of energy 5.11.5 5.21.6
n-3 PUFA, % of energy 0.650.2 0.710.2*
PUFA, % of energy 5.81.6 6.01.7
Animal fat, % of energy 15.95.5 15.15.1*
Vegetable fat, % of energy 14.04.4 14.14.5
Carbohydrate, % of energy 50.28.5 51.98.4
Fiber, g/d 19.18.2 19.28.4
Alcohol, g/d 14.719.4 7.211.8*
Drinkers, n (%) 751 (75) 768 (67)*
Smokers, n (%) 233 (23.3) 247 (21.6)
-Blocker treatment, n (%) 111 (11.1) 73 (6.3)*
Diabetes status, n (%) 74 (7.4) 44 (3.8)
On estrogen treatment, n (%) 0 (0) 90 (7.9)
APOA5 1131TC,‡ n (%)
TT 816 (86.2) 936 (87.0)
C carriers 131 (13.8) 140 (13.0)
APOA5 56CG,‡ n (%)
CC 860 (87.5) 1002 (89.1)
G carriers 123 (12.5) 123 (11.0)
Values are meanSD or n (%).
*Significantly different from men (P0.01).
†Data for these variables were available for only a random sample of these
participants (n1600).
‡APOA5 genetic data was successfully obtained in 947 men and 1076
women for the 1131TC polymorphism and for 983 men and 1125 women
for the 56CG polymorphism.
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subjects carrying the 1131C allele (Figure 1B) were
increased (34%, P0.005) when they consumed more
than 6% of energy from PUFAs. When we analyzed the
interaction of SNP 1131TC and PUFA intake in
determining LDL and VLDL sizes, we found statistically
significant interactions (P0.01 and P0.008, respec-
tively). These were consistent with a more atherogenic
lipid profile in subjects carrying the 1131C allele and
consuming more than 6% of energy from PUFAs. Thus, in
carriers of the 1131C allele, a high PUFA intake was
associated with smaller LDL particle size (20.600.05 nm
versus 20.800.03 nm in TT subjects) and also with larger
VLDL size (47.60.9 nm versus 46.50.5 nm in TT
subjects). Using the same statistical models in which fat
intake was dichotomized according to its corresponding
population mean, we did not uncover any significant
interactions between the APOA5 1131TC SNP and
intake of total fat, SFAs, or MUFAs on concentrations of
TGs, RLP-TGs, or RLP-C or on LDL and VLDL particle
size.
To investigate whether the interaction between PUFA
and APOA5 1131TC was dose dependent, we ana-
lyzed, as continuous variables, PUFA intake as well as the
intake of other fats to test the specificity of the effect. To
show the homogeneity by sex, separate models for men
and women (Table 2) were fitted with interactions between
fat intake (total fat, SFA, MUFA, and PUFA) and the
APOA5 polymorphism in determining TGs, RLP-TGs, and
RLP-C concentrations and LDL and VLDL particle size by
sex after controlling for potential confounders. Consistent
with results for the categorical variables, we found signif-
icant interactions between PUFA intake and 1131TC
SNP on TGs, RLP-TGs, RLP-C, and VLDL size in men
(P0.003, P0.001, P0.003, and P0.002, respec-
tively) and in women (P0.001, P0.001, P0.005, and
P0.004, respectively). Although the interaction for LDL
particle size was statistically significant only in men
(P0.004), the direction of the effect was similar in
women, and no significant heterogeneity by sex was found
(P0.211). In the combined analysis, all these interaction
terms with PUFA intake were significant. An example of
the modification of the effect of the SNP 1131TC by
PUFA intake on RLP-TG concentrations in men and
women combined can be seen in Figure 2. Differences in
slopes of the regression lines indicate that the effect of
1131TC on RLP-TG depends on the amount of PUFA
consumed. High PUFA intake was associated with lower
RLP-TG concentrations in TT individuals, whereas high
PUFA intake was associated with elevated RLP-TG con-
centrations in carriers of the C allele. To determine
whether the interaction effect on RLPs was dependent on
fasting TGs, we adjusted the regression models in Table 2
for fasting TGs. After this adjustment, the statistical
significance of the interaction term between the
1131TC polymorphism and PUFA intake in determin-
ing RLP decreased. For example, in the case of plasma
RLP-TGs, the probability value for the interaction term for
men and women (analyzed together) changed from
P0.001 (with no adjustment for fasting TGs) to P0.035
(after adjustment for fasting TGs), revealing some degree
of independence. However, considering the high correla-
tion between fasting TGs and RLP-TGs (r0.8, P0.001
in the present study), we cannot conclude a clear indepen-
dence of the effects. Finally, n-6 and n-3 FA intakes were
taken as 2 categorical variables, according to the popula-
tion mean (5.10% of energy for n-6 and 0.69% of energy
for n-3). Because no heterogeneity of the effects by sex
was detected, data for men and women were analyzed
together. After adjustment for covariates (sex, age, familial
relationships, BMI, smoking, alcohol use, total fat intake,
carbohydrates, energy intake, diabetes status, menopausal
status, -blocker use, and use of estrogens), statistically
significant interaction effects (P0.007) were found for
n-6 FA intake and the 1131TC polymorphism in
determining fasting TGs (1133 and 1143 mg/dL in TT
subjects versus 1207 and 1417 mg/dL in carriers of the
C allele when consuming less or more than 5.1% of energy
from n-6) and RLP-TGs (Figure 3A). No statistically
significant interactions were observed between the
1131TC and n-3 PUFA on fasting TGs (P0.668) or
RLP-TGs (Figure 3B). Results for RLP-TC and VLDL and
LDL particle size depending on the type of PUFA were
similar. Thus, statistically significant interactions were
Figure 1. Mean TG (A) and RLP-TG (B) concentrations in men
and women combined by APOA5 1131TC genotypes (gray
bar indicates TT; black bar, TCCC) and PUFA intake catego-
ries (PUFA 6% and PUFA 6%). Means were adjusted for
sex, age, familial relationships, BMI, smoking, alcohol, diabetes
status, menopausal status, estrogens, -blocker use, total fat
intake, carbohydrates, and energy. Mean values are antilog of
the log value. Bars indicate standard error (SE) of means. SEs
were computed to maintain the proportion estimated with the
log transformation.
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found for n-6 intake (P0.004, P0.006, and P0.01,
respectively), and nonsignificant interactions (P0.05) for
any parameter were detected in the case of n-3 PUFA. To
illustrate the possible dose-response relationship in this
interaction, n-6 and n-3 intake were considered as popu-
lation tertiles (4.37%, 4.37% to 5.54%, and 5.54% of
energy for n-6 and 0.58%, 0.58% to 0.74%, and 0.74%
of energy for n-3). We observed significant interactions
(P0.01) between 1131TC and n-6 PUFA intake on
the above variables with a clear dosage effect, whereas no
significant interactions (P0.05) between the 1131TC
polymorphism and n-3 PUFA were found. We present data
obtained for fasting TGs and RLP-TGs as examples. Thus,
a significant increase in TGs (26%) and RLP-TGs
(38%) was observed when n-6 PUFA intake increased
from the first to the third tertile in carriers of the 1131C
allele (1169, 1249, and 1468 mg/dL, respectively,
for TGs and 17.62.9, 18.53.4, and 24.33.5 mg/dL,
respectively, for RLP-TGs). However, no increase (0.1%,
P0.952) in TGs or even a nonsignificant decrease
(12%, P0.092) in RLP-TGs was observed in TT
homozygotes as n-6 PUFA increased. With regard to n-3
PUFA, no increase in TGs or in RLP-TGs in carriers of the
1131C allele was found. Moreover, in these subjects, a
decrease in RLP-TG was observed as PUFA intake in-
creased. This decrease in RLP-TG concentrations did not
reach statistical significance (P0.05), but it was statisti-
cally significant in TT homozygotes (23%, P0.005).
These results obtained with n-6 and n-3 PUFAs suggest
that the effect observed for total PUFAs may be specific to
the consumption of n-6 PUFAs.
Discussion
We found a significant and consistent interaction between the
APOA5 1131TC polymorphism (representing haplotype
APOA5*2)18 and PUFA intake on the concentration of
plasma TGs, RLP-TGs, and RLP-C as well as on VLDL and
LDL sizes in the Framingham Heart Study. This gene–diet
interaction was found in related and in unrelated subjects and
was not confounded by ethnicity. When PUFA consumption
was 6% (population mean) of total energy intake, carriers
of the 1131C allele exhibited significantly higher concen-
trations of fasting TGs and remnant lipoproteins (RLP-TGs
and RLP-C). Moreover, compared with TT individuals,
carriers of the 1131C allele displayed larger VLDL and
smaller LDL molecules, which have been reported to increase
CVD risk.35 This gene–diet interaction showed a clear
dose-dependent effect as well as a biologically plausible
TABLE 2. Interaction Between Fat Consumption (as Continuous) and the 1131T>C Polymorphisms on TG-Rich Particle
Concentrations and the Size of LDL and VLDL: Multiple Regression Analysis by the Type of Fat Consumed
Total Fat SFA MUFA PUFA
Men Women Men Women Men Women Men Women
B P B P B P B P B P B P B P B P
TG,* mg/dL
CTCC genotype 1.280 0.533 1.502 0.217 1.742 0.078 1.098 0.627 1.227 0.573 1.149 0.631 1.532 0.031 1.497 0.018
Fat intake 1.003 0.955 1.002 0.639 1.006 0.662 1.003 0.827 1.033 0.161 1.139 0.755 1.002 0.863 1.008 0.435
Interaction term 1.003 0.530 1.019 0.091 1.038 0.176 1.006 0.754 1.005 0.872 1.027 0.308 1.105 0.003 1.096 0.001
RLP-TG,* mg/dL
CTCC genotype 1.257 0.376 1.855 0.209 2.148 0.055 1.076 0.789 1.426 0.472 1.166 0.707 2.944 0.009 2.038 0.002
Fat intake 1.004 0.260 1.003 0.593 1.029 0.155 1.017 0.369 1.009 0.801 1.013 0.663 1.035 0.914 1.002 0.902
Interaction term 1.011 0.942 1.028 0.105 1.067 0.116 0.012 0.622 1.036 0.419 1.032 0.389 1.226 0.001 1.161 0.001
RLP-C,* mg/dL
CTCC genotype 1.014 0.575 1.267 0.403 1.757 0.016 1.121 0.446 1.115 0.681 1.001 0.998 2.291 0.003 1.439 0.016
Fat intake 1.002 0.584 1.002 0.303 1.013 0.267 1.014 0.129 1.011 0.549 1.013 0.414 1.023 0.029 1.006 0.437
Interaction term 1.018 0.866 1.012 0.245 1.047 0.022 1.002 0.754 1.015 0.529 1.009 0.665 1.172 0.003 1.075 0.005
LDL particle size, nm
CTCC genotype 0.453 0.110 0.151 0.604 0.112 0.670 0.079 0.653 0.409 0.193 0.034 0.886 0.519 0.012 0.116 0.396
Fat intake 0.004 0.352 0.003 0.425 0.011 0.448 0.018 0.129 0.001 0.976 0.038 0.055 0.001 0.919 0.022 0.057
Interaction term 0.017 0.069 0.008 0.433 0.024 0.299 0.001 0.974 0.047 0.071 0.001 0.641 0.111 0.002 0.032 0.135
VLDL particle size, nm
CTCC genotype 10.880 0.843 11.360 0.049 5.672 0.166 2.117 0.499 4.869 0.317 9.277 0.036 8.404 0.031 8.907 0.008
Fat intake 0.048 0.512 0.074 0.282 0.473 0.053 0.107 0.669 0.041 0.929 0.581 0.101 0.443 0.071 0.215 0.297
Interaction term 0.100 0.575 0.404 0.042 0.538 0.136 0.253 0.404 0.412 0.328 0.885 0.029 1.409 0.004 1.553 0.004
Adjusted P values and regression coefficients (B, in milligrams per deciliter or nanometers, depending on the trait) for the main effect (genotype and fat) and
interaction terms in men and women. Multivariate regression models for each type of fat and lipid trait were fitted. Models were adjusted for age, body mass index,
familial relationships, smoking, alcohol, diabetes, estrogens, menopause, -blockers, energy intake, carbohydrates, and total fat intake. The TT genotype was
considered the reference category for the APOA5 1131TC polymorphism.
Slopes for the TT and C carriers for each type of fat can be easily obtained: The corresponding fat intake term is the TT slope; the TCCC genotype term  the
corresponding interaction term  the TT slope is the slope for carriers of the C allele for each lipid variable.
*For log-transformed variables, antilog values were calculated.
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association consistent with the expected metabolic pathways
involved.12,15,16 Two additional findings add interest to this
observation. First, the interaction observed for SNP
1131TC was not shared by SNP 56CG, which repre-
sents the other common APOA5*3 (56CG) haplotype,18
despite the fact that we reported similar associations between
these 2 haplotypes and plasma TRL concentrations.22 The
contrasting results suggest that the hypertriglyceridemic phe-
notype associated with these 2 haplotypes is driven by
different mechanisms. Thus, the causative mutation for the
APOA5*2 haplotype appears to be associated with dietary
fat, whereas that of the APOA5*3 haplotype may not be
modulated by fat intake. Second, the reported interactions are
exclusively due to consumption of PUFA, with no interac-
tions detected for total fat, SFA, or MUFA, adding evidence
to the prominent role of PUFAs as modulators of genetic
effects in lipid metabolism.25 Although it has been proposed
that postprandial TRLs could be independent CVD risk
factors and although the hypothesis is physiologically
sound,36 we found significant gene–PUFA intake interaction
for both fasting TG and RLP concentrations. Given the fact
that fasting TGs are highly correlated with RLP-TGs, we
cannot conclude in the present study a clear independence of
the effects on both variables. This is consistent with recent
findings that have failed to support such independence at the
population level.37,38 Therefore, it will be important from a
scientific point of view to clarify the role of remnants in
atherogenesis by using appropriate experimental designs;
however, from a clinical point of view, the measurement of
total TGs appears to be a reasonable and practical surrogate to
identify disturbances in TRL metabolism and gene–diet
interactions.
Because n-3 and n-6 FAs differ in their potential
preventive effect on CVD,39 we further investigated
whether the PUFA interaction applied to the consumption
of both families of PUFAs. Our results support the notion
that the above-reported interactions are specific to n-6
PUFA. The potentially negative effects associated with
elevated lipoprotein remnant concentrations observed in
carriers of the APOA5 1131C allele who consume high
n-6 PUFA were not observed for the consumption of n-3
PUFA. In fact, dietary n-3 FAs decreased RLP and related
variables regardless of genotype. Similar findings have
been reported for the arachidonate 5-lipoxygenase gene.
Promoter variants at this locus are associated with in-
creased atherosclerosis, and this association is promoted
by dietary n-6 PUFA and inhibited by marine n-3
PUFAs.40
The relevance of these findings for CVD risk detection
and prevention lies in the correlation between fasting and
postprandial TG metabolism and CVD risk.3,41 Fruchart-
Najib et al11 reported that overexpression of human
APOA5 diminished postprandial TG response to sunflower
Figure 2. Scatterplot of the observed values (open squares indi-
cate TT allele carriers; asterisks, C allele carriers) and regression
lines of predicted values (broken lines indicate TT allele carriers;
solid lines, C allele carriers) of RLP TG concentration by APOA5
1131TC genotypes (in men and women combined, n1527)
depending on the PUFA consumed (as a continuous variable).
Predicted values were calculated from the regression models
containing PUFA intake, 1131TC polymorphism, their inter-
action term, and the potential confounders (sex, age, familial
relationships, BMI, smoking, alcohol, diabetes status, meno-
pausal status, total fat intake, carbohydrates, estrogens,
-blocker use, and energy). R2 of the model0.14; P0.001.
Figure 3. Mean RLP TG concentration in men and women com-
bined depending on n-6 PUFA (A) and n-3 PUFA (B) categories
(below and above the population mean) and APOA5 1131TC
genotypes (TT or 1131C carriers). Means were adjusted for
sex, age, familial relationships, BMI, smoking, alcohol, diabetes
status, menopausal status, estrogens, -blocker use, total fat
intake, carbohydrates, and energy. Mean values are antilog of
the log value. Bars indicate standard error (SE) of means. SEs
were computed to maintain the proportion estimated with the
log transformation.
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oil in mice. Therefore, the observed differences between
carriers of different alleles at APOA5 1131TC, al-
though still controversial,42 may be due to their differential
expression. On the basis of the correlation between fasting
and postprandial TG concentrations, we anticipate that
compared with TT homozygotes, the APOA5 1131C
minor allele will result in higher postprandial lipemia. In
this regard, Jang et al24 demonstrated that carriers of the
1131C allele had a higher chylomicron-TG area under
the curve than did homozygotes for the 1131T allele
after a fat load enriched in n-6 PUFA. Conversely, the
allelic differences were not significant when subjects were
provided with a low fat load.24 Martin et al23 also reported
that male carriers of the 1131C allele had significantly
higher lipemic responses to a fat tolerance test. However,
the responses were not significantly different by genotype
after adjustment for fasting TG concentrations. Moreover,
Masana et al,43 reported that carriers of the C allele had
similar or even lower incremental diurnal triglyceridemia
than did wild-type carriers after correction for fasting TG
concentrations. We speculate that the high saturated fat
meal used by Dwyer et al40 prevented the manifestation of
the increased postprandial load, which appears to be
preferentially driven by n-6 PUFA.
There is no proven mechanistic explanation for our
differential findings for n-6 and n-3 FAs. However, on the
basis of the evidence that TRLs are hydrolyzed by the
lipolytic action of dimeric LPL, which is bound to heparan
sulfate proteoglycans on the vascular endothelium, one can
speculate that APOA5 targets VLDL to proteoglycans,
placing VLDL in proximity to LPL.14 –17 Moreover,
APOA5 may activate proteoglycan-bound LPL by stabi-
lizing the dimerized conformation or by binding to an LPL
allosteric site. An important feature of this model is that
for all this to happen efficiently, LPL and APOA5 must be
in contact with proteoglycans on the endothelial cell
membrane.17 In other words, there is margination or
sequestration away from the blood of TRL during binding
to endothelial LPL. The concept of margination has been
illustrated by Park et al.44 Most interesting is the fact that
the amount of sequestration is dependent on the type of
dietary fat. A diet rich in n-3 FAs promotes the margin-
ation of the TRLs, whereas a diet rich in n-6 FAs does not
promote, and may even inhibit, the margination of TRLs.
Therefore, we propose the following: (1) In subjects with
the most common APOA5 genotype, there is normal
APOA5-induced margination of TRLs and normal hydro-
lysis of these lipoproteins. (2) In subjects carrying the
1131C allele, there is less APOA5 available and less
margination of TRLs, with subsequently increased levels
of TRL, which may be accentuated in particles enriched in
n-6 FAs.45 (3) Increased presence of n-3 FA strongly
enhances TRL margination by yet-unknown mechanisms
but probably independent of APOA5 levels. These effects
overwhelm those milder effects associated with the
APOA5 variant.
These findings could be relevant within the context of
future development of personalized dietary recommenda-
tions because the frequency of the 1131C allele varies
across ethnic groups, ranging from 0.07 in whites to 0.20
in Africans, 0.30 in Hispanics, and up to 0.40 to 0.50 in
Chinese and Japanese populations.9,21,22 It is interesting to
note that most dietary intervention studies using PUFA-
rich diets have been performed in non-Hispanic whites,46
in whom frequencies of the high-TG–associated APOA5
alleles are relatively low. Hence, the overall CVD risk
associated with the 1131C allele in the presence of high
n-6 PUFA diets may not be apparent for the population as
a whole.
In summary, the observed interaction between APOA5
and PUFA consumption on TGs, RLP concentrations, and
lipoprotein particle sizes suggests that higher n-6 PUFA
intake increases plasma TGs and RLPs and decreases LDL
particle size in carriers of the 1131C allele, contributing
to a more atherogenic lipid profile for this subset of the
population. Most interesting, this interaction was not
observed for n-3 PUFA.
Medical societies and government bodies have em-
braced the concept of nutrition as a major player in the
epidemic of cardiovascular disease (CVD) and potentially
in its control. However, some scientists remain uncertain
about what constitutes the optimal diet for atherosclerosis
prevention and therapy. One of the major reasons for this
uncertainty is the lack of conclusive results from dietary
clinical trials. The bases for the inconsistencies are the
many other factors affecting CVD risk and risk factors,
including age, sex, physical activity, alcohol use, smoking,
and genetic background. A more complete understanding
of these factors and a thoughtful use of this information
should help in the identification of vulnerable populations
or persons who will benefit from more personalized and
mechanistic-based dietary recommendations. This poten-
tial for better prevention and therapy can be developed
within the context of nutritional genomics that may pro-
vide the tools to achieve effective dietary prevention and
therapy for CVDs. In summary, some time in the future,
clinicians will be able to quickly identify a patient’s DNA
profile for coronary artery disease risk and then get
immediate information on his or her metabolic response to
a particular diet. The findings of this research contribute to
this future by showing that high dietary PUFA n-6 may not
result in atherosclerosis protection for a subpopulation of
subjects characterized by the presence of the polymor-
phism in the promoter region of the APOA5 gene. How-
ever, this subgroup may substantially benefit from in-
creased PUFA n-3 consumption.
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CLINICAL PERSPECTIVE
Medical societies and government bodies have embraced the concept of nutrition as a major player in the epidemic of
cardiovascular disease (CVD) and potentially in its control. However, some scientists remain uncertain about what
constitutes the optimal diet for atherosclerosis prevention and therapy. One of the major reasons for this uncertainty is the
lack of conclusive results from dietary clinical trials. The bases for the inconsistencies are the many other factors affecting
CVD risk and risk factors, including age, sex, physical activity, alcohol use, smoking, and genetic background. A more
complete understanding of these factors and a thoughtful use of this information should help in the identification of
vulnerable populations or persons who will benefit from more personalized and mechanistic-based dietary recommenda-
tions. This potential for better prevention and therapy can be developed within the context of nutritional genomics that may
provide the tools to achieve effective dietary prevention and therapy for CVDs. In summary, some time in the future,
clinicians will be able to quickly identify a patient’s DNA profile for coronary artery disease risk and then obtain immediate
information on his or her metabolic response to a particular diet. The findings of this research contribute to this future by
showing that high dietary PUFA n-6 may not result in atherosclerosis protection for a subpopulation of subjects
characterized by the presence of the polymorphism in the promoter region of the APOA5 gene. However, this subgroup
may substantially benefit from increased PUFA n-3 consumption.
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